Table 3 Pathways which are overexpressed in all patients, and in the subgroups of IFN high and IFNlow patients, all compared with healthy controls, analysed by gene set enrichment analysis.
| Pathway | No. of genes | All patients | IFNhigh | IFNlow |
|---|---|---|---|---|
| p Value | p Value | p Value | ||
| Type I IFN‐induced genes22 | 83 | 0.004 | <0.001 | NS |
| IFNα‐induced21 | 36 | 0.022 | <0.001 | NS |
| IFNβ‐induced21 | 51 | NS | <0.001 | NS |
| Cytokine–cytokine receptor interaction | 129 | 0.006 | 0.005 | NS |
| Neuroactive ligand–receptor interaction | 90 | 0.009 | NS | <0.001 |
| Jak‐STAT signalling pathway | 86 | 0.016 | 0.008 | NS |
| Complement and coagulation cascades | 44 | 0.025 | 0.009 | NS |
| Fatty acid metabolism | 41 | 0.027 | 0.015 | NS |
| IFNγ‐induced21 | 34 | NS | 0.019 | NS |
IFN, interferon; NS, nonsignificant.
Pathways are shown with a p value <0.05, and a false discovery rate value <0.25.